NeuroSense Therapeutics Receives Nasdaq Noncompliance Notice; Co. Plans To Appeal
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases,
Share
Why It Matters
NeuroSense got a warning from Nasdaq that it broke a rule. The company says it will fight the warning in court.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.